Enzalutamide + PEMBROLIZUMAB for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Nov 2018: Trial registered, NCT03753243
  2. 3 Dec 2018: Trial started, NCT03753243

The trials

NCT03753243: Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

State
Under way
Phase
Phase 2
People
32 planned
Started
3 Dec 2018
Primary completion
3 Sep 2022
Arms
Intervention
Results
None posted
  1. 26 Nov 2018: Trial registered
  2. 3 Dec 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.